NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

US-Iran Conflict Escalation Raises Concerns for US Economy and Stock Market

As the US midterm election approaches in November, the escalating conflict with Iran poses a significant risk to the US economy. A prolonged escalation could lead to weaker consumer sentiment and adverse voter perception, thereby heightening economic risks. However, US President Donald Trump appears intent on bringing the conflict to a close, with a 2-3 week timeframe to end the war.

The objectives of the conflict remain unclear, with multiple parties operating under divergent objectives. Israel appears inclined to continue the conflict across Iran and Lebanon, a stance reportedly supported by several Gulf nations. In contrast, Iran is seeking assurances against future strikes and compensation for losses. This dynamic may translate into heightened volatility through April, even as it keeps the prospect of de-escalation alive.

The conflict's impact on the stock market is also a concern. The short-lived conflict has raised the risk of spillover effects on FY27 earnings forecasts. The domestic market's decline in March was a deliberate correction, down 11.3% MoM and 15.3% from the Nifty 50's 52-week high. The key consideration is duration: the longer the conflict persists, the greater the potential economic and earnings damage.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

IndicatorFY26FY27 (Estimated)
Crude Price$69/bblElevated, but exact price unknown
Earnings Growth14-16%12-14% (with 2-6% drag)

Given the extent of damage to regional oil infrastructure and the risk that near-term rhetoric continues to support hostilities, crude prices are likely to remain elevated in FY27 relative to the FY26 average of $69/bbl. This environment could pressure the earnings outlook, with an initial estimate of a 2-6% drag, depending on the trajectory of crude and macroeconomic developments in Q1FY27.

Persistent earnings downgrades would also weigh on India's premium valuation. In this decade, India has traded at an average one-year forward P/E of 20x, materially above the 2010-2020 average of 15x. A preliminary assessment implies an average 4% reduction in India's EPS, which would translate into a revised target of ~26,600, assuming a 1x compression in the forward P/E to 19.5x.

Overall, the medium-term set-up looks constructive. Based on Thursday's close, a nominal return of 15% to 20% appears feasible, assuming the conflict concludes during April to May. The decline has extended into April and has taken the Nifty 50 index to a new intraday low of 22,182, which is 16% below the 52-week high recorded in January.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Investor Takeaway

Investors should be cautious of potential market volatility due to US-Iran tensions.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.